Contact Us

Maravai LifeSciences Expands Oligonucleotide Business, Leases New Facility for TriLink BioTechnologies

(September 10, 2018) -

Maravai LifeSciences, a leader in providing reagents to researchers, biotherapeutics manufacturers and OEM partners worldwide, today announced plans to relocate and expand its TriLink BioTechnologies operations with the signing of a lease on a new facility in the Sorrento Valley area of San Diego. TriLink will consolidate its San Diego facilities into a new 95,000-square-foot space with an option to expand for future growth. The new facility will house the company’s current local staff of more than 150 and can accommodate growth to more than 350 R&D, commercial and manufacturing employees. The company’s current Good Manufacturing Practice (cGMP) production capabilities will also be relocated, validated and expanded.

TriLink will be the lead tenant in the 180,000-square-foot building, which is located at 10770 Wateridge Circle. The company will begin its move in the fall of 2019, with completion by the end of the year. Maravai LifeSciences corporate headquarters will also relocate to the new building.

"This new facility and related investments we are making in the business position us well for the continuing growth we foresee,” said Brian Neel, chief operating officer for TriLink. “We can now further scale up our chemistry and biological operations in a state-of-the-art facility and meet the demand for our products in the growing fields of gene editing and DNA/RNA therapeutics and diagnostics. The new space will also enable us to create individual cGMP suites that can be tailored for customer campaigns."

About Maravai LifeSciences

Maravai LifeSciences is committed to catalyzing the growth of successful, entrepreneurial, life science companies by providing expertise, capital, processes and systems. Maravai LifeSciences companies provide tools and services to pharmaceutical and biopharmaceutical research and development companies to enable breakthrough discoveries and improvements in human well-being. The Maravai LifeSciences portfolio includes Vector Laboratories, TriLink BioTechnologies, Cygnus Technologies and Glen Research. Maravai LifeSciences is a portfolio company of GTCR, a leading private equity firm focused on investing in growth companies in financial services, technology and information services and healthcare.


Contacts for the media:

Jennifer Dahlgren
Dahlgren Communications
[email protected]

David Weber, Chief Commercial Officer
Maravai LifeSciences
(650) 464-4908
[email protected]